Business
Presentation of Scientific Data
Presentation of Scientific Data.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nKidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences\nFour new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients\n \nLONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American Diabetes Association 83rd Scientific Sessions (June 23-26, 2023) in San Diego, California and another abstract has been accepted at the American Association of Nurse Practitioners National Conference (June 20-25, 2023) in New Orleans, Louisiana.\n \nAccepted abstracts reflect the growing body of scientific evidence demonstrating the important role KidneyIntelX serves towards advancing patient care and awareness for early-stage diabetic kidney disease. The presentations at the American Diabetes Association 83rd Scientific Sessions meeting include late-breaking data from a multi-year real-world evidence study, extended validation of KidneyIntelX, and a cost-effectiveness analysis addressing economic benefit in the VA population. In addition to multiple data presentations, Renalytix will be hosting three medical education events covering real-world evidence data unveiled at the conference so that clinicians may discuss and engage with the Renalytix leadership team as well as their peers in nephrology, endocrinology, and primary care providers.\n \nAmerican Diabetes Association 83rd Scientific Sessions presentations will be displayed over three days June 24-26, 2023, and moderated at the specified times below. Presentations related to KidneyIntelX will also be published on the journal Diabetes® website.\n\n\n\n\n \n· Late-breaker Presentation: \"Clinical Impact of Risk Profiling with KidneyIntelX on DKD Progression in a Large Integrated Health Care System\" will be presented by Dr. Joji Tokita, principal investigator of the multi-year real-world evidence study and practicing clinician at the Mount Sinai Health System and moderated on Saturday, June 24, 2023, from 11:30am-12:30pm PDT.\n \n· &...